As of 2026-03-15, the Intrinsic Value of Neurocrine Biosciences Inc (NBIX) is 119.92 USD. This NBIX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 129.78 USD, the upside of Neurocrine Biosciences Inc is -7.60%.
The range of the Intrinsic Value is 80.24 - 278.18 USD
Based on its market price of 129.78 USD and our intrinsic valuation, Neurocrine Biosciences Inc (NBIX) is overvalued by 7.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 80.24 - 278.18 | 119.92 | -7.6% |
| DCF (Growth 10y) | 106.60 - 365.46 | 158.87 | 22.4% |
| DCF (EBITDA 5y) | 97.81 - 130.13 | 108.31 | -16.5% |
| DCF (EBITDA 10y) | 114.87 - 163.59 | 132.17 | 1.8% |
| Fair Value | 120.00 - 120.00 | 120.00 | -7.54% |
| P/E | 43.01 - 131.46 | 91.89 | -29.2% |
| EV/EBITDA | 73.48 - 117.92 | 90.91 | -29.9% |
| EPV | 47.43 - 64.88 | 56.15 | -56.7% |
| DDM - Stable | 27.06 - 94.38 | 60.72 | -53.2% |
| DDM - Multi | 38.38 - 114.12 | 58.65 | -54.8% |
| Market Cap (mil) | 12,940.36 |
| Beta | 0.80 |
| Outstanding shares (mil) | 99.71 |
| Enterprise Value (mil) | 12,227.36 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.50% |
| Cost of Debt | 5.00% |
| WACC | 8.06% |